-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Microchip Biotech's announcement, the company's product, siglita sodium tablets, successfully renewed the “National Medical Insurance Catalogue”. The drug is classified as Class B, and the agreement is valid from January 1, 2027 to December 31, 2028. Siglistat sodium is the world's first PPAR full agonist approved for marketing, discovered exclusively by the company. It is used to treat type 2 diabetes, and was included in the national health insurance catalogue for the first time in 2023. The new medical insurance catalogue will be implemented on January 1, 2027, and is not expected to have a significant impact on the company's operating performance during the reporting period.
Share
Listen to the news
According to Microchip Biotech's announcement, the company's product, siglita sodium tablets, successfully renewed the “National Medical Insurance Catalogue”. The drug is classified as Class B, and the agreement is valid from January 1, 2027 to December 31, 2028. Siglistat sodium is the world's first PPAR full agonist approved for marketing, discovered exclusively by the company. It is used to treat type 2 diabetes, and was included in the national health insurance catalogue for the first time in 2023. The new medical insurance catalogue will be implemented on January 1, 2027, and is not expected to have a significant impact on the company's operating performance during the reporting period.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending